Evolus, Inc. income statement

In fiscal 2025, Evolus, Inc. reported revenue of $297m, up 11.6% on the year before, operating income of −$32.7m (a -11.0% margin) and net income of −$51.6m, or −$0.80 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evolus, Inc.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	35	57	100	149	202	266	297	316
Cost of revenue	0	8	18	44	59	65	84	100	105
Gross profit	0	27	38	56	90	138	182	197	211
Research and development	6	4	2	2	5	7	9	10	10
Selling, general and administrative	29	114	98	112	142	165	198	221	217
Operating income	−46	−99	−153	−44	−65	−49	−34	−33	−19
Interest expense	1	—	—	1	9	14	19	20	16
Income before tax	−47	−105	−163	−47	−74	−62	−50	−51	−34
Income tax	0	−15	0	0	0	0	1	1	1
Net income	−47	−90	−163	−47	−74	−62	−50	−52	−34
Diluted EPS	−$1.92	−$3.19	−$4.83	−$0.94	−$1.33	−$1.08	−$0.81	−$0.80	−$0.53
Diluted shares (average)	24m	28m	34m	50m	56m	57m	62m	64m	65m
EBITDA	−46	−95	−146	−39	−62	−44	−29	−25	−11

US$ millions unless shown otherwise. Fiscal quarters.

Evolus, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	61	79	69	69	69	90	73	84
Cost of revenue	19	26	22	24	23	31	24	27
Gross profit	42	53	47	45	46	59	49	57
Research and development	2	2	2	2	2	3	2	2
Selling, general and administrative	53	50	57	57	53	55	52	57
Operating income	−15	−2	−15	−10	−12	4	−7	−5
Interest expense	5	5	4	7	4	4	4	4
Income before tax	−19	−6	−19	−17	−16	1	−10	−8
Income tax	0	0	0	0	0	0	0	−0
Net income	−19	−7	−19	−17	−16	0	−11	−8
Diluted EPS	−$0.30	−$0.10	−$0.30	−$0.27	−$0.24	$0.00	−$0.16	−$0.12
EBITDA	−14	−1	−14	−9	−10	6	−5	−3

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EOLS vs XERS EOLS vs HROW EOLS vs IRWD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Evolus, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evolus, Inc.